Have a feature idea you'd love to see implemented?
Let us know!
CMPX Compass Therapeutics Inc
Price (delayed)
$1.38
Market cap
$189.87M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.36
Enterprise value
$159.95M
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in
Highlights
Compass Therapeutics's quick ratio has soared by 99% from the previous quarter and by 70% YoY
The net income has declined by 17% year-on-year
The equity has contracted by 14% YoY and by 5% from the previous quarter
Key stats
What are the main financial stats of CMPX
Market
Valuations
Earnings
Shares outstanding
137.59M
Market cap
$189.87M
Enterprise value
$159.95M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.37
Price to sales (P/S)
223.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
188.18
Revenue
$850,000
EBIT
-$47.76M
EBITDA
-$45.9M
Free cash flow
-$48.1M
Per share
Balance sheet
Liquidity
EPS
-$0.36
Free cash flow per share
-$0.35
Book value per share
$1.01
Revenue per share
$0.01
TBVPS
$1.08
Total assets
$149.15M
Total liabilities
$10.75M
Debt
$6.88M
Equity
$138.4M
Working capital
$136.71M
Debt to equity
0.05
Current ratio
31.84
Quick ratio
30.54
Net debt/EBITDA
0.65
Margins
Efficiency
Dividend
EBITDA margin
-5,399.6%
Gross margin
100%
Net margin
-5,618.7%
Operating margin
-6,523.2%
Return on assets
-30.7%
Return on equity
-32.4%
Return on invested capital
-37.9%
Return on capital employed
-33%
Return on sales
-5,618.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CMPX stock price
How has the Compass Therapeutics stock price performed over time
Intraday
0.73%
1 week
-13.21%
1 month
-25.41%
1 year
-18.34%
YTD
-11.54%
QTD
-25%
Financial performance
How have Compass Therapeutics's revenue and profit performed over time
Revenue
$850,000
Gross profit
$850,000
Operating income
-$55.45M
Net income
-$47.76M
Gross margin
100%
Net margin
-5,618.7%
The net income has declined by 17% year-on-year
The operating income has decreased by 16% YoY
Growth
What is Compass Therapeutics's growth rate over time
Valuation
What is Compass Therapeutics stock price valuation
P/E
N/A
P/B
1.37
P/S
223.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
188.18
The EPS has declined by 9% year-on-year
The equity has contracted by 14% YoY and by 5% from the previous quarter
CMPX's price to book (P/B) is 9% lower than its last 4 quarters average of 1.5
Efficiency
How efficient is Compass Therapeutics business performance
Compass Therapeutics's return on assets has decreased by 39% YoY and by 4.4% QoQ
The ROIC has contracted by 37% YoY and by 4.7% from the previous quarter
The return on equity has declined by 37% year-on-year and by 4.9% since the previous quarter
Dividends
What is CMPX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CMPX.
Financial health
How did Compass Therapeutics financials performed over time
Compass Therapeutics's quick ratio has soared by 99% from the previous quarter and by 70% YoY
CMPX's current ratio has soared by 97% from the previous quarter and by 74% YoY
CMPX's debt is 95% smaller than its equity
The equity has contracted by 14% YoY and by 5% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.